CTOs on the Move

Renovia Incorporated

www.renoviainc.com

 
Renovia was formed to develop and commercialize products for better first-line diagnosis and treatment to improve the condition-specific quality of life for millions of women with pelvic floor disorders. Renovia`s technology enables treatment via precise visualization of pelvic movement in real-time during pelvic floor muscle training, while monitoring usage and progress over time. As a women`s health organization, Renovia is in pursuit of scalable and cost-effective care for pelvic floor disorders delivered through the power of digital health.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Funding

Renovia Incorporated raised $17M on 04/19/2021

Similar Companies

Fine Science Tools

Fine Science Tools is a San Mateo, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ShiraTronics

ShiraTronics is in the early stages of developing new innovative therapies to combat debilitating migraine headache. ShiraTronics is focused on commercializing novel neuromodulation technologies to treat this large unmet clinical need for patients and physicians.

Montvale Technologies

Montvale Technologies is a Montvale, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

SSCOR

SSCOR is a Sun Valley, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

LumiThera

At LumiThera, we are committed to developing solutions to prevent vision loss and blindness, improve visual function and stop or slow the progression of blinding diseases of the eye. We will continue to innovate non-invasive approaches to address unmet medical needs. LumiThera, Inc. is a commercial-stage medical device company initially focused on treating patients affected by dry age-related macular degeneration. The Company`s expertise is in the application of photobiomodulation (“PBM”), using non-invasive light emitting diodes (“LED”) for acute and chronic ocular diseases and disorders. The Company is developing an ophthalmic LED office-based instrument to be used in multiple ocular conditions or disorders as non-invasive medical treatments. Three clinical studies have demonstrated clinical and pathological benefits of PBM in treating subjects with dry AMD. The recent TORPA II clinical trial results demonstrating improvements in clinical outcomes of vision and reduction of pathological “drusen” following imaging analysis were published in December 2016 in ACTA Ophthalmologica, a top peer-reviewed Ophthalmology journal. The company recently completed the LIGHTSITE I clinical trial,a thirty subject dry AMD study partially supported by the National Eye Institute. The Valeda LIght Delivery System is now available for sale in the European Economic Area. The Valeda Light Delivery System is CE Marked. The device is not for sale in the USA.